Peptide News Digest

#Melanoma

7 stories

Melanoma coverage on Peptide News Digest is dominated by peptide cancer vaccine work. The most cited 2026 read: a randomized Phase I/II trial of a melanoma helper peptide vaccine combined with anti-CD27 antibody varlilumab reported 69% four-year disease-free survival in the combination arm versus 20% with vaccine alone — though varlilumab depleted circulating CD4+ T cells, raising questions about the mechanism.

Other threads: Evaxion's EVX-01 in melanoma, the Mel39 trial, and adjuvant immunotherapy work pairing peptide vaccines with checkpoint inhibitors. Several AACR 2026 abstracts also covered peptide-vaccine programs in melanoma.

Stories here cover trial readouts, AACR and ASCO presentations, and the broader peptide-vaccine field in melanoma. See #peptide-vaccine, #cancer-vaccine, and #mel39-trial.

Clinical Trials · View digest

Evaxion's Personalized Peptide Vaccine EVX-01 Produced T Cells Detectable Without Lab Expansion in Melanoma Patients, Company Says at SITC

Evaxion reported at the Society for Immunotherapy of Cancer meeting in Phoenix that its AI-designed EVX-01 vaccine, given with Merck's Keytruda in a 16-patient Phase 2 trial in advanced melanoma, produced neoantigen-specific T cells that could be detected directly ex vivo. CD4+ T cells dominated those responses, and CD8+ responses appeared in half of patients. The trial previously reported objective responses in 12 of 16 patients at two years, including four complete responses, but it had no comparison arm.

Research · View digest

Case Report: Man Develops New Melanoma Weeks After Injecting Melanotan II Bought at a Gym

Doctors in Illinois and Michigan described in JAAD Case Reports a 46-year-old man with a history of melanoma who began daily injections of Melanotan II, an unapproved tanning peptide, bought at a local gym, Gizmodo reported on October 8, 2026. About five weeks later he noticed moles changing size, shape, and color and stopped; a biopsy about a month after that confirmed an early-stage melanoma. He also used tanning beds two to three times a week and had taken anabolic steroids, so the authors could not rule out other causes, and they warned about unregulated peptides promoted on social media.

Clinical Trials · View digest

Evaxion to Present New Immune Data for Its AI-Designed Personalized Peptide Vaccine EVX-01 Plus Keytruda in Melanoma at SITC 2026

Evaxion said on Friday, October 2, 2026 that it will present new immune data from its Phase 2 trial of EVX-01, a personalized, AI-designed peptide cancer vaccine given with Merck's Keytruda (pembrolizumab) to 16 patients with advanced melanoma, at the Society for Immunotherapy of Cancer meeting in Phoenix, with an oral presentation on November 6. Previously reported two-year results showed objective responses in 12 of 16 patients (75%), including four complete responses, and tumor-specific immune responses to 86% of the vaccine's neoantigen targets. Each patient receives a vaccine designed and manufactured from their own tumor's biology.

Clinical Trials · View digest

Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) Announced Wednesday August 19, 2026 That the Phase 3 INTerpath-001 Trial of Intismeran Autogene (V940 / mRNA-4157, an Individualized Neoantigen Therapy) Plus Pembrolizumab (Keytruda) Met Its Primary Endpoint of Recurrence-Free Survival (RFS) and Key Secondary Endpoint of Distant Metastasis-Free Survival (DMFS) in Adults With High-Risk (Stage IIB-IV) Resected Cutaneous Melanoma Compared to Keytruda Alone; The Readout Is the First Positive Phase 3 for an Individualized Neoantigen Therapy and the First Phase 3 to Demonstrate Substantial Improvement Over Keytruda Alone in the Adjuvant Melanoma Setting; Phase 2b KEYNOTE-942 Five-Year Follow-Up Data Presented at ASCO 2026 Had Shown a 49% Reduction in Risk of Recurrence or Death and a 59% Reduction in Risk of Distant Metastasis or Death Versus Keytruda Alone

Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) announced Wednesday August 19, 2026 that the Phase 3 INTerpath-001 trial of intismeran autogene (V940 / mRNA-4157, an individualized neoantigen therapy) plus pembrolizumab (Keytruda) met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in adults with high-risk (Stage IIB-IV) resected cutaneous melanoma compared to Keytruda alone. Mechanism: intismeran autogene is a personalized mRNA therapy that encodes up to 34 tumor-specific neoantigen peptides selected from the individual patient's tumor mutation signature. The mRNA is delivered as a lipid nanoparticle injection; cells at the injection site translate the mRNA into the neoantigen peptides, which are then presented to the immune system to generate a targeted T-cell response against the patient's tumor. The Phase 3 readout is the first positive Phase 3 for an individualized neoantigen therapy and the first Phase 3 to demonstrate substantial improvement over Keytruda alone in the adjuvant melanoma setting. Trial design: randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 evaluating safety and efficacy of the combination versus Keytruda alone. Phase 2b KEYNOTE-942 five-year follow-up data presented at the 2026 ASCO Annual Meeting had shown a 49% reduction in risk of recurrence or death and a 59% reduction in risk of distant metastasis or death for the combination versus Keytruda alone, and the Phase 3 readout confirms and extends those benefits. The result validates the personalized neoantigen mRNA vaccine platform and opens a substantial commercial pathway for the Merck-Moderna collaboration in adjuvant oncology settings beyond melanoma including non-small-cell lung cancer, renal cell carcinoma, and cutaneous squamous cell carcinoma where INTerpath studies are ongoing.

Research · View digest

International Journal of Cancer: 20-Year Follow-Up of the Mel39 Multipeptide Melanoma Vaccine Trial Reports 49% Overall Survival Across Both Arms

A post-hoc analysis in the International Journal of Cancer followed 51 patients from the Mel39 randomized Phase 2 trial, in which people with resected stage IIB-IV melanoma received a vaccine of 4 or 12 melanoma peptides. At a median follow-up of 16.1 years (21.2 years for living participants), overall survival across both arms was 65% at 10 years and 49% at 20 years. Survival favored the 12-peptide vaccine (hazard ratio 0.64, 95% CI 0.29-1.40), but the difference was not statistically significant (p = 0.26), and the authors concluded that adding more peptides did not significantly improve clinical efficacy; women had significantly better recurrence-free survival than men after either vaccine.

Clinical Trials · View digest

Evaxion EVX-01 Personalized Peptide Vaccine Achieves 75% ORR at 2 Years in Metastatic Melanoma

Evaxion's AI-designed personalized neoantigen peptide vaccine EVX-01 combined with Keytruda produced a 75% objective response rate at 2 years in advanced melanoma patients, with 86% of vaccine targets triggering de novo T-cell responses. Data were presented April 22 at AACR 2026; 3-year follow-up expected in H2 2026. The 86% target-hit rate demonstrates AI-designed peptide neoantigen selection maturing for cancer vaccines.